Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia

@article{Gentile2000ComparativeES,
  title={Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia},
  author={Sandro Gentile and Salvatore Turco and Giuseppina Guarino and Carla Sasso and M I Amodio and P Magliano and Teresa Salvatore and Gerardo Corigliano and Mariano Agrusta and Giovanni de Simone and Iole Gaeta and Biagio Oliviero and Roberto Torella},
  journal={Diabetes},
  year={2000},
  volume={2}
}
Although there is little information from primary or secondary prevention trials on cholesterol‐lowering medication in diabetic patients, the reduction of elevated cholesterol is widely recommended for this group. The American Diabetes Association (ADA) recommends drug therapy in diabetic patients if low density lipoprotein (LDL)‐cholesterol remains at > 130 mg/dl, or > 100 mg/dl in patients with macroangiopathy, after dietary intervention. When cholesterol‐lowering medication is indicated, the… Expand
View on Wiley
ncbi.nlm.nih.gov
56 Citations
Highly Influential Citations
1
Background Citations
13
Methods Citations
2
Results Citations
3

56 Citations

Citation Type

Citation Type

Comparative efficacy and safety of atorvastatin, simvastatin and lovastatin in the management of dyslipidemic Type 2 diabetic patients
Comparative efficacy and safety of atorvastatin, simvastatin and lovastatin in the management of dyslipidemic Type 2 diabetic patients
TLDR
The results of this study confirm that among statins, atorvastatin is a better choice for the control of hyperlipidemia in Type 2 diabetic patients. Expand
Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus.
TLDR
Atorvastatin was effective at reducing the risk of a first major cardiovascular event, including stroke, in a large, placebo-controlled, multicentre trial in patients with type 2 diabetes and at least one other coronary heart disease (CHD) risk factor, but without markedly elevated LDL-cholesterol levels. Expand
Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics
TLDR
The results of the study will provide important information on the efficacy and safety of atorvastatin to support its use in patients with an impaired renal function who are at a high risk of vascular morbidity and mortality. Expand
Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
TLDR
It is suggested that atorvastatin beneficially alters the atherogenic lipid profile in patients with combined dyslipidemia and significantly decreases the density of LDL particles produced resulting in a shift from small, dense LDL to more buoyant and less Atherogenic particles. Expand
Atorvastatin
The introduction of statins has drastically changed the treatment and prevention of atherosclerotic vascular disease. By lowering lipid levels and reducing the risk of coronary heart disease, these… Expand
Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
TLDR
Atorvastatin is an appropriate first-line lipid-lowering therapy in numerous groups of patients at low to high risk of CHD and has a definite role in treating patients requiring greater decreases in LDL-cholesterol levels. Expand
Switching From Atorvastatin to Simvastatin in Patients at High Cardiovascular Risk: Effects on Low-Density Lipoprotein Cholesterol
TLDR
A large proportion of patients who switch from atorvastatin to simvastsatin are prescribed doses that are not therapeutically equivalent, and these patients were significantly less likely to meet LDL-C treatment goals compared with patients who remained on atorVastatin. Expand
Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
  • F. Hobbs
  • Medicine
  • International journal of cardiology
  • 2006
TLDR
Clinical trials evaluating both primary and secondary prevention of CVD demonstrate that lipid-lowering therapy results in a substantial reduction of cardiovascular risk in patients with type 2 diabetes. Expand
A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin.
TLDR
Atorvastatin was 2 to 4 times as potent as simVastatin in reducing TC, LDL-C, and TG, indicating that the dose equivalence of atorvASTatin and simvastsatin lay between 1:2 and 1:4, but higher doses of simvstatin were more effective in increasing HDL-C levels than atoravastatin, with no apparent dose-equivalence point. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 64 REFERENCES
Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia.
TLDR
Atorvastatin 10 and 20mg once daily is superior to pravastatin 20 and 40 mg once daily in treating patients with hypercholesterolemia and neither treatment caused clinically relevant laboratory abnormalities. Expand
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.
TLDR
Atorvastatin is highly effective and well tolerated in patients with primary hypercholesterolemia with no increased risk of adverse events and safety profiles were similar for the 2 reductase inhibitors. Expand
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
The objective of this multicenter, randomized, open-label, parallel-group, 8-week study was to evaluate the comparative dose efficacy of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase… Expand
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia
TLDR
Atorvastatin caused significantly greater reductions from baseline than did simVastatin for LDL cholesterol, total cholesterol, very low density lipoprotein cholesterol, triglycerides, and apolipoprotein B (p <0.05); this cholesterol-lowering profile affords utility in many patient types. Expand
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
TLDR
Atorvastatin caused significantly greater reductions from baseline than did simVastatin for LDL cholesterol, total cholesterol, very low density lipoprotein cholesterol, triglycerides, and apolipoprotein B (p <0.05); this cholesterol-lowering profile affords utility in many patient types. Expand
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.
TLDR
Atorvastatin was well tolerated by hyperlipidemic patients, had an acceptable safety profile, and provided greater reduction in cholesterol than other previously reported HMG-CoA reductase inhibitors. Expand
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
TLDR
This study shows that long-term treatment with simvastatin is safe and improves survival in CHD patients, and a 37% reduction in the risk of undergoing myocardial revascularisation procedures. Expand
Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin.
TLDR
Lovastatin, as an adjunct to diet for the reduction of elevated LDL cholesterol, was generally very well tolerated. Expand
Gemfibrozil Alone and in Combination With Lovastatin for Treatment of Hypertriglyceridemia in NIDDM
TLDR
The beneficial effects of the combination therapy on lipoprotein levels in markedly hypertriglyceridemic NIDDM patients could decrease the risk of development of both acute pancreatitis and CHD. Expand
Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus.
TLDR
The beneficial effects of lovastatin on plasma lipid levels in patients with NIDDM could decrease the risk of the development of coronary heart disease. Expand
...
1
2
3
4
5
...